Sangamo Therapeutics Inc. (NASDAQ: SGMO) Could Bring Massive Returns? – Marketing Sentinel
Home  »  Science   »  Sangamo Therapeutics Inc. (NASDAQ: SGMO) Could Bri...

Sangamo Therapeutics Inc. (NASDAQ: SGMO) Could Bring Massive Returns?

In the last trading session, 3.3 million shares of the Sangamo Therapeutics Inc. (NASDAQ:SGMO) were traded, and its beta was 1.54. Most recently the company’s share price was $3.94, and it changed around $0.36 or 10.06% from the last close, which brings the market valuation of the company to $535.96M. SGMO currently trades at a discount to its 52-week high of $12.83, offering almost -225.63% off that amount. The share price’s 52-week low was $3.12, which indicates that the current value has risen by an impressive 20.81% since then. We note from Sangamo Therapeutics Inc.’s average daily trading volume that its 10-day average is 2.39 million shares, with the 3-month average coming to 1.61 million.

Sangamo Therapeutics Inc. (NASDAQ:SGMO) trade information

Instantly SGMO has showed a green trend with a performance of 10.06% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.08 on Tuesday, 06/21/22 increased the stock’s daily price by 3.43%. The company’s shares are currently down -47.47% year-to-date, but still up 20.12% over the last five days. On the other hand, Sangamo Therapeutics Inc. (NASDAQ:SGMO) is -1.50% up in the 30-day period. We can see from the shorts that 8.06 million shares have been sold at a short interest cover period of 7.17 day(s).

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Sangamo Therapeutics Inc. (SGMO) estimates and forecasts

Sangamo Therapeutics Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -51.77 percent over the past six months and at a -15.45% annual growth rate that is well below the industry average of 0.60%. Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will loss -6.10% in revenue this quarter, and will report a decrease of -12.10% in the next quarter. The year-over-year growth rate is expected to be -6.00%, down from the previous year.

Consensus estimates provided by 9 financial analysts predict the company will bring in an average of $24.63 million in revenue for the current quarter. 9 analysts expect Sangamo Therapeutics Inc. to make $24.87 million in revenue for the quarter ending Sep 2022. Forecasts for the next quarter put sales growth at -1.30%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -4.00%.

SGMO Dividends

Sangamo Therapeutics Inc.’s next quarterly earnings report is expected to be released around May 02 and May 06.

Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 16.91% of Sangamo Therapeutics Inc. shares, and 55.25% of them are in the hands of institutional investors. The stock currently has a share float of 66.50%. Sangamo Therapeutics Inc. stock is held by 277 institutions, with Blackrock Inc. being the largest institutional investor. By Mar 30, 2022, it held 7.92% of the shares, which is about 11.62 million shares worth $67.48 million.

Wasatch Advisors Inc, with 7.47% or 10.96 million shares worth $82.21 million as of Dec 30, 2021, holds the second largest percentage of outstanding shares.

Wasatch Ultra Growth Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF were the top two Mutual Funds as of Mar 30, 2022. The former held 4.28 million shares worth $24.87 million, making up 2.92% of all outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held roughly 4.21 million shares worth around $25.39 million, which represents about 2.87% of the total shares outstanding.

Leave a Comment

Your email address will not be published.

On Key

Related Posts